These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22840301)

  • 1. Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
    Rahalkar AR; Ban MR; Hegele RA
    Can J Cardiol; 2013 Apr; 29(4):418-22. PubMed ID: 22840301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk.
    Boh M; Opolski G; Poredos P; Ceska R; Jezovnik M
    Int Angiol; 2011 Aug; 30(4):366-74. PubMed ID: 21747355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid profile changes associated with changing available formulary statins: removing higher potency agents.
    Longyhore DS; Stockton CM; Thomas MR
    Am J Manag Care; 2009 Jul; 15(7):409-14. PubMed ID: 19589008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
    Folse H; Sternhufvud C; Andy Schuetz C; Rengarajan B; Gandhi S
    Clin Ther; 2014 Jan; 36(1):58-69. PubMed ID: 24417785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
    J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
    Ogata N; Fujimori S; Oka Y; Kaneko K
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins: is it safe and effective to use generic "equivalents"?
    Jackevicius CA; Tu JV; Krumholz HM
    Can J Cardiol; 2013 Apr; 29(4):408-10. PubMed ID: 23062664
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
    Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
    Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.